Kornimate/medical-research-clean huggingface dataset:
effects of integrated neuromuscular training on physical fitness in badminton athletes with different maturity statuses

Conditions: Athletic Injuries

Summary: dominant leg use in badminton may contribute to lower limb asymmetry, potentially affecting performance and injury risk. this study investigated the effects of a 12-week integrated neuromuscular training (nmt) program on sport performance in 24 well-trained male badminton players, grouped by maturation status (pre- and post-peak height velocity; n = 12 each). all participants completed two nmt sessions weekly. pre- and post-training assessments included 20-m sprint, countermovement jump (cmj), agility t-test, hexagon test, and y-balance test.

this study aimed to evaluate the effects of integrated nmt on lower extremity sports performance in pre-phv and post-phv male badminton players. a parallel, two-group, stratified randomized controlled design was employed. the intervention lasted 12 weeks, with two sessions per week. all dependent variables were assessed at baseline and after 12 weeks. following the training period, participants completed sport-specific performance tests, including the 20-m linear sprint, countermovement jump, agility t-test, hexagon test, and y-balance test.twenty-four well-trained male badminton players with a mean age of 13.5 ± 1.15 years participated in this study . the results of this study underscore the importance of maturation status in determining how youth athletes respond to integrated nmt interventions.

Eligibility criteria:
inclusion criteria: - male badminton athletes with no lower limb injuries within 6 months exclusion criteria: * female athletes and athletes with lower limb injuries

Keywords: strength asymmetry maturation injury
joint management of dm2 and pulmonary tb in orizaba, veracruz

Conditions: Pulmonary Tuberculosis; Diabetes Mellitus, Type 2

Summary: the objective of this study is to evaluate an integral strategy in which diabetes mellitus 2 (dm2) and pulmonary tuberculosis (tb) are managed together. the researchers propose a community intervention with two arms in 4 health centers in orizaba, veracruz. patients will be assigned to either arm by convenience. one arm will receive the joint treatment strategy and another the routine treatment used in health services.

in mexico dm2 is the main complication of patients with tb (22.2%), more so than hiv, malnutrition and chronic pulmonary obstructive disease (copd). the world health organization (who) has proposed a framework for the joint management of tb and dm2 and one of the key points is the need for studies that evaluate the viability and efficacy of programs that manage both diseases jointly. there are social and clinical determinants that are associated to a higher mortality in patients with dm2 and tb such as poor glucose level control (glycosylated hemoglobin \>7mg/dl) and immunosuppression which in turn increases the risk of developing a recurrent episode of tb, being multi drug resistant (mdr) and/or failing tb treatment. the determinants associated to tb are the lack of awareness of the disease, drug toxicity and interaction with dm2 medication and treatment default. social determinants are low income level, living in a crowded household, living in rural areas, not having access to health care, having been in prison and living with people with tb. the strategy consists of interventions on patients, health personnel, community health workers and directors of health services. researchers will train patients in the use of glucometers, health personnel in management of comorbidities of dm2 and tb, health workers in how to support patients and increase treatment adherence. bidirectional screening in patients with tb or dm2 using bacilloscopies and glycosylated hemoglobin (hba1c). during the 6 months of directly observed treatment (dots) study nurses will monitor levels of glucose weekly with capillary glucose, monthly with fasting glucose, in months 1, 3 and 6 with hba1c. patients with high glucose levels will be referred to metabolic control which will be assessed by experts. regarding dots, first line tb drugs will be available and study nurses will supervise that they are taken correctly. a nutritionist will carry out home visits to guide dietary intake.

Eligibility criteria:
inclusion criteria: * diagnosis of active ptb, diagnosis of dm2, not having started tb treatment, attend a selected health clinic, sign a written informed consent exclusion criteria: * unable to provide information, pregnancy, hiv infection
efficacy of self vs. physician application of triamcinolone-econazole in otomycosis

Conditions: Otomycosis

Summary: to analyze the clinical characteristics, types of fungal infections, and comparison of the efficacy of patient self-application versus physician application of triamcinolone acetonide econazole cream in otomycosis treatment.

the study analyzes the clinical characteristics, including symptoms and physical examinations, as well as the types of fungal infections. it compares the efficacy of patient self-application versus physician application of triamcinolone acetonide econazole cream in treating otomycosis two weeks after starting treatment. furthermore, the study also compares the recurrence rates six months after treatment.

Eligibility criteria:
inclusion criteria: * 1.the chief complaint was ear discomfort, including tinnitus, a feeling of blockage or fullness, pruritis, otalgia, otorrhea and decreased hearing; 2. physical examination findings:presence of fungal hyphae or accumulations that appear creamy or cheese-like or resembling abnormal earwax (crusts, films) , skin redness, erosion, swelling, or granulation tissue within the ear canal; 3. positive results in fungal culture. exclusion criteria: * the exclusion criteria included otitis media, tympanic membrane perforation, and conditions post-radiotherapy.

Keywords: triamcinolone acetonide econazole cream otomycosis
nasal mask and prong use in non-invasive ventilation for newborns

Conditions: Bronchopulmonary Dysplasia

Summary: the study aims to investigate efficacy and safety of nasal mask and prongs used in non-invasive ventilation in newborns by using esophageal pressure transducer. the parameters including ventilation duration, hospitalization duration, pulmonary outcomes and side effects will be evaluated.

although it seems as more non-invasive there is still lack of data especially on efficacy of nasal mask use in niv for newborns. by using esophageal pressure transducers we will evaluate the pressure supplied by the ventilation mode and compare it with more commonly used nasal prongs. the investigators will test the hypothesis of equivalence of nasal mask in comparison to prongs with better safety parameters.

Eligibility criteria:
inclusion criteria: * all newborns who require niv as first line treatment as respiratory support in delivery room or neonatal intensive care unit exclusion criteria: * who are intubated in delivery room or neonatal intensive care unit before randomization * with congenital anomaly * patients who require niv more than 3 days

Keywords: cpap failure bronchopulmonary dysplasia nasal trauma ventilation duration non-invasive ventilation
the effect of new dentifrices containing centella asiatica and bamboo salt on reducing plaque and gingivitis

Conditions: Labor Trial Refused

Summary: this study aims to evaluate the effect of dentifrice formulations containing centella asiatica and bamboo salt on gingivitis and dental plaque. participants uses dentifrice which contains centella asiatica and bamboo salt and the same participants will also use placebo for tooth brushing by cross-over design.

with growing interest in plant-based products among researchers, many toothpastes with various herbal extracts have been introduced over the past few decades,centella asiatica (ca), a small herb broadly cultivated in china, southeast asia, india and oceanic countries, has long been used for therapeutic purposes since ancient times.ca has been reported to be useful in the treatment of skin diseases wound repair and healing of burn. in dentistry, few studies have explored the efficacy of ca. in one study, ca was demonstrated to be an effective supportive agent following periodontal treatment, resulting in reduced plaque and gingivitis. in spite of such wound healing properties of ca, its usage in dental field has been limited. bamboo salt (bs) is a korean folk remedy consisting of sea salt roasted in bamboo which has long been used for therapeutic purposes in korea. toothpastes containing bs has been sold in korea for some decades. some in vitro studies and animal studies using rats demonstrated anti-inflammatory effects of bs. nevertheless, no human study has yet evaluated the effect of bs on periodontal health. therefore, the new dentifrice containing ca and bs was developed.

Eligibility criteria:
inclusion criteria: * systemical healthy individual * normal alignment of teeth exclusion criteria: * recent antibiotic treatment * existence of dental caries or periodontitis * those needs emergency dental treatments * natural teeth less than 20 * denture wearer * oral appliance for orthodontic treatment * pregnant

Keywords: centella asiatica bamboo salt dentifrice
comparison of 68ga-fapi-46 pet and 18f-fdg pet in lung cancer

Conditions: Lung Cancer

Summary: this is a prospective, single-center, single arm, open label study to evaluate the performance of 68ga-fapi-46 for the diagnosis of primary and metastatic lesions of lung cancer with comparison to 18f-fdg pet.

fdg-pet imaging is recommended by clinical guidelines for staging of lung cancer; however, there are still limitations of fdg-pet in lung cancer staging due to false-positive and false-negative findings. 68ga-fapi pet images have shown high diagnostic performance with high tumor-to-background ratio in various cancers. the purpose of this study is head-to-head comparison of 68ga-fapi-46 pet and 18f-fdg pet for the diagnosis and staging or re-staging of lung cancer.

Eligibility criteria:
inclusion criteria: 1. age \> 20 years 2. informed consent obtained from patients and families 3. patients with histology confirmed lung cancer or patients with ggo on chest ct planned to have biopsy or surgery 4. patients scheduled to undergo fdg-pet examination 5. performance status: 0, 1, 2, 3 exclusion criteria: 1. contraindication to fapi-pet and fdg-pet such as pregnant, or lactating patients 2. patients with mainly malignant pleural effusion without other measurable lesions 3. undergoing irradiation at accrual 4. active infection or other serious underlying medical conditions not compatible with study entry 5. history of significant neurological or psychiatric disorders including dementia that would prohibit the understanding and giving of informed consent

Keywords: 68ga-fapi-46 lung cancer
hepatocyte transplantation as a life support bridge

Conditions: Fulminant Liver Failure

Summary: the purpose of this study is to gain knowledge about the result of infusing liver cells, carefully matched to blood type, into a subject's body. the hope is that this procedure will aid functions of the liver and prevent death, enable a transplant procedure to be carried out if a donated liver becomes available, and lessen complications in postoperative recovery. there is no guarantee that any of these benefits will be re eived, but even if they are not, the hope is that knowledge gained by using this procedure will be of future benefit to others who also suffer from liver disease.

adult and pediatric patients eligible for liver transplantation who require intensive care unit admission for multisystem organ failure in addition to liver failure, without systemic sepsis, are eligible for liver cell transplantation regardless of race, sex or financial support. failure of 3 or more organ systems are the criterion used to select patients with as close to 100% mortality as possible without solid organ transplant. hepatocytes, isolated from excess liver tissure from reduced liver transplant procedures or from donor livers not used for transplantation, are prepared by a complex process and then are infused, guided by radiology into the splenic artery or portal vein of the patient. patients must be on immunosuppression therapy for as long as the hepatocytes are living and beneficial to the patient.

Eligibility criteria:
inclusion criteria: * patients admitted to vcu health system icu in fulminant liver failure in addition to multisystem organ failure exclusion criteria: patients with sepsis -

Keywords: hepatocytes
peg-rhg-csf in lymphoma patients after autologous hematopoietic stem cell transplantation

Conditions: Lymphoma

Summary: the purpose of the study is to evaluate the efficacy and safety of peg-rhg-csf on the recovery of hematopoietic function after autologous stem cell transplantation in patients with lymphoma.

at present, there is few related research of recombinant human granulocyte colony-stimulating factor applying to ahsct in china. the purpose of the study is to evaluate the efficacy and safety of peg-rhg-csf in lymphoma patients after autologous hematopoietic stem cell transplantation. eligible patients were randomly assigned to peg-rhg-csf group or rhg-csf group. patients in peg-rhg-csf group received peg-rhg-csf day +1 after transplantation with a dose of 100μg/kg. patients with the weight more than 45kg were suggested a dose of 6 mg. patients in control group received rhg-csf day +1 after transplantation with a dose of 5μg/kg once per day until the recovery of neutrophil.

Eligibility criteria:
inclusion criteria: 1. patients with age between 18 and 65 years. 2. lymphoma patients with the requirement for autologous hematopoietic stem cell transplantation. 3. the collected cd34+ cells≥1×10e6/kg. 4. ecog score ≤2. 5. heart and lung is normal. 6. blood creatinine ≤1.5×uln. 7. alt, ast, tbil ≤2 ×uln 8. not in pregnancy. 9. written informed consent are acquired. exclusion criteria: 1. had received autologous hematopoietic stem cell transplantation or allogeneic transplantation. 2. severe or uncontrolled infectious diseases: hiv, hcv, syphilis, alt, chronic hepatitis b. 3. serious complications, such as severe infection, heart, lung, liver and kidney dysfunction. 4. lvef \<55%. 5. allergic to the product or other biological products from genetically engineered escherichia coli strains. 6. refused to take contraceptive measures during the study period and the subsequent 1 years. 7. severe mental or neurological disorders. 8. serious heart, lung, central nervous system disorders. 9. sickle cell anemia, hemolytic anemia and other hematologic diseases. 10. participate in other drugs clinical trials 30 days before the screening. 11. other situation that investigators consider as contra-indication for this study. -
hexaminolevulinate (hal) photodynamic therapy (pdt) of cervical intraepithelial neoplasia (cin) grade 1

Conditions: Cervical Intraepithelial Neoplasia

Summary: the study will examine the effect of hal vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.

low-grade cervical intraepithelial neoplasia (cin1) is caused by persistent hpv infection and may worse case develop into cancer. in most cases both the virus infection and lesions (cin1) regress spontaneously, but must be followed up with gynecological examinations to ensure normalization. if further persistent disease and worsening to precancerous lesions (cin2-3), the usual treatment is surgery, where one removes the tissue in the cervix where the cin lesions are. in this research study we will evaluate a new non-surgical treatment for cin1 using hexaminolevulinate (hal) photodynamic therapy (pdt). hal pdt is the combination of a medication and a specific type of light to activate the drug. hal pdt selectively removes cin lesions while preserving normal tissue, thus this may be an alternative to frequent gynecological consultations and local surgery that may have undesirable side effects.

Eligibility criteria:
inclusion criteria: * satisfactory colposcopy examination * negative endocervical canal by colposcopy * ectocervical cin1 as verified by local pathologist (biopsy). * colposcopical visible lesion at visit 2, before photoactivation * written informed consent signed * age 18 or above exclusion criteria: * previous treatment of cin or invasive disease or suspicion of either micro-invasive or invasive disease * malignant cells on cytology or histology * atypical glandular cells (agc) or adenocarcinoma in situ (ais) on cytology * suspicion of endocervical disease on colposcopy * current pelvic inflammatory disease, cervicitis, or other gynecological infection as per colposcopy and clinical examination * known or suspected porphyria * known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid) * use of heart pacemaker * pregnancy * nursing * childbirth or miscarriage within six weeks of enrolment - known * participation in other "competitive" clinical studies either concurrently or within the last 30 days * risk of poor protocol compliance * not willing to use adequate birth control from screening until last pdt * subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

Keywords: cervical intraepithelial neoplasia (cin)
follow-up of aki in neonates during childhood years

Conditions: Neonatal Acute Kidney Injury; Childhood Chronic Kidney Disease

Summary: the purpose of this study is to learn more about how to identify signs of early chronic kidney diseases in children who were born prematurely with low birth weight (less than 3 ½ pounds). researchers plan to compare the kidney function in children who experienced acute kidney injury (aki) in the neonatal intensive care unit (nicu) with those who did not experience it. evidence from several studies and our experience at uva show that older children who experienced aki while in the pediatric intensive care unit (picu) have increased risk of developing early chronic kidney disease, and they also show early changes in the urine and blood that is consistent with early chronic kidney disease. in this study, the investigators hope to determine if any of these changes can be detected in early childhood, and if so, at what age we can start detecting these changes.


Eligibility criteria:
inclusion criteria: * premature birth for premature groups * uva nicu admission prior to 2 days of life * birth weight less than 1500 grams for premature groups * premature aki study group: acute kidney injury as defined by kdigo modified criteria during nicu stay at uva * premature no aki control group: no aki during nicu stay * term no aki control group: no aki and born at term * parental or legal guardian consent obtained exclusion criteria: - patients with congenital anomalies of the kidney and urinary tract
modulation of insulin sensitivity by betaine upregulation of fgf21

Conditions: Insulin Sensitivity

Summary: people with poor insulin sensitivity do not respond normally to elevations in blood sugar. this may increase their risk of developing diabetes in the future. the purpose of this research study is to determine if the nutrient betaine, found in beets, spinach and wheat products, can enhance the production of fetal growth factor 21 (fgf21), a molecule that is believed to promote insulin sensitivity.

aim: to determine if betaine is a modulator of fgf21 in humans. low plasma betaine is associated with an increased risk of metabolic syndrome, but the mechanisms modulating this correlation are poorly delineated. betaine bioavailability in humans is determined by dietary intake and genetic polymorphisms that influence betaine metabolism. therefore, moderating betaine levels could be particularly beneficial for some individuals. fgf21 is elevated in response to insulin insensitivity and is under active investigation as a therapeutic modality. the mechanisms of action of fgf21 and betaine on insulin sensitivity in humans are incompletely understood. this study tests the hypothesis that betaine induces fgf21 secretion and insulin sensitizing actions in humans by measuring plasma fgf21, betaine, choline (betaine precursor), glucose, insulin and adiponectin in response to betaine supplementation over a 24 hour time course in 20 healthy, lean individuals. this pilot nutrition intervention will provide key preliminary evidence for understanding whether and how betaine exerts metabolic benefit in humans and will inform a future study to investigate the novel betaine-fgf21-insulin sensitivity axis in a larger cohort.

Eligibility criteria:
inclusion criteria: * healthy * able/willing to consume study meals * non-smoker * bmi in normal range (18-24.9) exclusion criteria: * use of chronic medications * abnormal physical examination or chronic illness * use of drugs or medications known to alter choline/betaine metabolism * consumption of more than 2 oz of alcohol/day or 24 oz wine/day * use of choline/betaine-containing dietary supplements during the previous 3 months * diagnosed with cystathionine beta-synthase (cbs) deficiency * pregnant or breastfeeding * known hypersensitivity to betaine * current substance abuse or addiction
characterization of the postural habits of wheelchair users analysis of the acceptability of international recommendations in the prevention of pressure sores risk by using a connected textile sensor

Conditions: Duchenne Muscular Dystrophy; Spinal Muscular Atrophy

Summary: spinal cord injuries and people with duchenne muscular dystrophy or infant spinal muscular atrophy (isa) are prone to pain and pressure sores associated with prolonged sitting. for this reason, it is recommended that people with spinal cord injuries release pressure every 15 to 30 minutes and motorized wheelchair users use the electric positioning functions at least 1 minute every hour. the aim is to prevent and/or reduce pain and pressure sores. these devices could help to observe daily the variability of users' pressure maps, their impact on occupational performance, the link with pain and redness and could propose customized adjustments.

the main objective of this study is to evaluate the impact of an algorithm that characterizes the cruro-ischiatic fingerprints used in daily life and that issues an alert in case of detection of a pressure sore risk defined by the literature on the occupational performance of the subjects. the resulting assumption is based on the following points: * the algorithms implemented in this device are able to calculate and isolate a number of cruro-ischiatic fingerprints used during the day during priority activities and active or passive position changes. * they may, in the event of a risk position, issue alerts based on the recommendations. this will allow us to analyze the impact of these alerts on the changes in position and relief actually performed by the subject, analyze the consequences on the mcro score (psychosocial impact on occupational performance) and verify the impact of visual biofeedback on chair positioning.

Eligibility criteria:
inclusion criteria: * men or women over 18 years of age, * daily user of a fr (more than 3 hours per day): * persons with duchenne muscular dystrophy (dmd) or dmb using an fre, * people with infant spinal muscular atrophy (isa) using an fre, * wb persons using an mra with sensitivity disorders (asia a). * fre allowing a switchover of at least: * 25° of the seat and 120° of the backrest, * 45° of sitting in one block, * patient who has signed an informed and written consent, * affiliation to a social security scheme (beneficiary or beneficiary). exclusion criteria: * refusal of the patient to participate in the study, * school level lower than cycle 3 not allowing to understand the use of the embedded device, * severe incontinence, * bm without sensitivity disorders, * participant in another study or therapeutic trial, * patient under guardianship or curatorship, * pregnant women.